Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q2- Text added to 2023 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
accredited, Adimab, adjusted, adjustment, allopurinol, American, Antigen, Asia, astrocytoma, axillary, Brazil, Brunei, California, Cambodia, captioned, Chimeric, Chinese, CIRM, COH, cold, CUSIP, Deadline, discover, district, DOSPA, durable, Eastern, entry, eradicated, exempt, exhausting, FBIOP, fifteen, GABAA, GBM, glycopyrronium, highest, Hong, hot, hydrate, hypericemia, indemnity, India, indirect, indolent, Indonesia, intratumoral, Jiangsu, Kong, Korea, latent, lawsuit, living, Macau, Malaysia, motion, mutually, Myanmar, nonrefundable, Orphan, PIPE, Plantation, posed, proportional, proportionate, reclassified, refractory, Regenerative, reserved, retroactively, rGBM, select, Singapore, South, specialty, Street, subcontracting, Taiwan, Tamid, Tennessee, Thailand, tiered, tosylate, unauthorizedly, unvested, unwritten, UTRF, Vietnam, vigorously, wholly, winding, yen
Valuein 2023 Q2 filing- Value in 2023 Q3 filing
Original filings
Filing view